Methotrexate (MTX) is a commonly used chemotherapeutic agent. Oxidative stress and inflammation have been proved in the development of MTX toxicity. Paeonol is a natural phenolic compound with various pharmacological activities including antioxidant and anti-inflammatory properties. The aim of the present study was to evaluate the protective effect of paeonol against MTX-induced cardiac toxicity in rats and to evaluate the various mechanisms that underlie this effect. Paeonol (100 mg/kg) was administered orally for 10 days. MTX cardiac toxicity was induced at the end of the fifth day of the experiment, with or without paeonol pretreatment. MTX-induced cardiac damage is evidenced by a distortion in the normal cardiac histological structure, with significant oxidative and nitrosative stress shown as a significant increase in NADPH oxidase-2, malondialdehyde, and nitric oxide levels along with a decrease in reduced glutathione concentration and superoxide dismutase activity compared to the control group. MTX-induced inflammatory effects are evidenced by the increased cardiac toll-like receptor 4 (TLR4) mRNA expression and protein level as well as increased cardiac tumor necrosis factor- (TNF-) α and interleukin- (IL-) 6 levels along with increased nuclear factor- (NF-) κB/p65 immunostaining. MTX increased apoptosis as shown by the upregulation of cardiac caspase 3 immunostaining. Paeonol was able to correct the oxidative and nitrosative stress as well as the inflammatory and apoptotic parameters and restore the normal histological structure compared to MTX alone. In conclusion, paeonol has a protective effect against MTX-induced cardiac toxicity through inhibiting oxidative and nitrosative stress and suppressing the TLR4/NF-κB/TNF-α/IL-6 inflammatory pathway, as well as causing an associated reduction in the proapoptotic marker, caspase 3.

1. Introduction

Methotrexate (MTX), a cytotoxic chemotherapeutic drug with folate antagonistic activity, is commonly used in the treatment of various types of malignancies such as lymphoma [1]. It is also used at a low dose in the treatment of several autoimmune diseases such as rheumatoid arthritis [2]. MTX primarily inhibits the dihydrofolate reductase enzyme and secondarily inhibits purines and pyrimidines necessary for DNA and RNA synthesis; as a consequence, both contribute to the cytotoxic effects of MTX [3]. The cytotoxic effects of MTX are not restricted to tumor cells but also extend to affect vital organs [4] including the heart [5], where the inhibitory action of MTX on glyoxalase and antioxidant
systems may also contribute to the toxicity of the drug [6]. Several agents have been used, with various degrees of success, to prevent MTX cardiac toxicity [7, 8].

Paeonol, a phenolic compound isolated from *Paeonia suffruticosa*, has been shown to have a wide range of pharmacological activities including antioxidant and anti-inflammatory properties [9] that may be beneficial in various diseases such as diabetes [10], cancer [11], gastric ulcer [12], liver fibrosis [13], and myocardial infarction [14]. Paeonol has been proven to have a protection against antineoplastic-induced toxicities such as cisplatin-induced nephrotoxicity [15] and epirubicin-induced cardiac toxicity [16]; however, to date, this role has not been investigated in MTX-induced cardiac toxicity.

Toll-like receptor 4 (TLR4), an important member of the TLR family, activates nuclear factor-κB and enhances production of inflammatory mediators such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) [17]. Thus, as TLR4 is expressed in cardiomyocytes [18], they are implicated in the development and progression of different myocardial inflammations such as myocarditis [19], myocardial infarction [20], ischemia-reperfusion injury [21], and heart failure [22]. In addition, TLR4 antagonists improved various cardiovascular diseases [23, 24]. Therefore, the aim of the current study was to evaluate the protective effect of paeonol in MTX-induced cardiac toxicity in rats and to evaluate the various mechanisms that underlie this effect.

## 2. Materials and Methods

### 2.1. Chemicals and Antibodies

Paeonol (2′-hydroxy-4′-methoxyacetophenone; molecular weight: 166.17; 99% pure powder) was purchased from Sigma-Aldrich Corp. (St. Louis, MO, USA). MTX was purchased from Minapharm Pharmaceuticals (Cairo, Egypt), and ready-to-use NF-κB/p65 and caspase 3 rabbit polyclonal antibodies were purchased from Thermo Fisher Scientific Inc. (Waltham, MA, USA). Rat TLR4, TNF-α, and IL-6 enzyme-linked immunosorbent assay (ELISA) kits were purchased from Elabscience (Houston, TX, USA). All other chemicals were obtained from commercial sources.

### 2.2. Experimental Design

Male Wistar rats weighing 180–210 g were used after 1 week for proper acclimatization to the animal house conditions (12 h lighting cycle and 25 ± 2 °C temperature). Rats were housed three rats per cage, and they had free access to commercial laboratory chow and tap water throughout the experiment. The animal ethical standards were in accordance with EU directive 2010/63/EU. Animals were divided into three groups (*n* = 6 each): (a) the control nontreated group, (b) the MTX-treated group that received a single intraperitoneal dose of 20 mg/kg MTX [25] at the end of the fifth day of the experiment, and (c) the MTX/paeonol-treated group treated by a single daily oral dose of 100 mg/kg paeonol suspended in carboxymethyl cellulose [26] for ten consecutive days and received MTX at the end of the fifth day of the experiment.

### 2.3. Sample Preparation

After 5 days of MTX injection, total body weights of rats were recorded, then rats were sacrificed and hearts were dissected out. Cardiac samples were homogenized in 10% w/v ice-cold phosphate buffer (0.01 M, pH 7.4). The homogenate was centrifuged at 3000 rpm for 20 min, and the supernatant was used for the estimation of NADPH oxidase- (NOX-) 2, malondialdehyde (MDA), nitric oxide (NO), reduced glutathione (GSH), TLR4, TNF-α, and IL-6 levels along with superoxide dismutase (SOD) activity. Ventricular samples were kept in 10% neutral-buffered formalin for histopathological and immunohistochemical examinations. Cardiac tissue samples were kept at -80°C for the determination of the TLR4 gene using real-time polymerase chain reaction (PCR).

### 2.4. Histopathological Evaluation of the Cardiac Damage

Cardiac specimens were fixed in 10% neutral-buffered formalin, embedded in paraffin, sectioned at 5 μm thickness, and stained with hematoxylin and eosin. A modified scoring system was done according to Li et al. [14] and Moreno Júniur et al. [27]. Ten fields of vision for each group were selected. Histological changes such as necrosis of myofibers, hemorrhage, and inflammatory cell infiltration were scored on a 4-point scale: (−) negative, indicating no necrotic foci; (+) mild, indicating one or two small foci of myocardial necrosis, with scattered areas of hemorrhage and a slight degree of inflammatory process; (++) moderate, indicating more than two areas of small foci of myocardial necrosis, with a few areas of hemorrhage and a diffuse inflammatory process; and (+++) severe damage, indicating confluent foci of myocardial necrosis, with many areas of hemorrhage and massive areas of inflammation.

### 2.5. Evaluation of Cardiac Oxidative and Nitrosative Stress Markers

Oxidative stress markers were determined in a cardiac homogenate where NOX-2, MDA, NO, and GSH levels as well as SOD activity were evaluated. For quantitative determination of NOX-2, the Rat NOX-2 ELISA Kit (Bioassay Technology Laboratory, Shanghai, China) was used according to the manufacturer’s instructions. The MDA level was determined by the assessment of thiobarbituric acid reacting substance through spectrophotometric measurement of color at 535 nm, and the results were expressed as nmol/g tissue [28]. NO determination, an indicator of nitrosative stress, was done chemically by the Griess method, which estimates the stable oxidation end products of NO, namely, nitrite (NO$_2^-$) and nitrate (NO$_3^-$), as indicators of NO production. The principle of the assay is the reduction of NO$_2^-$ to NO$_3^-$ by copperized cadmium granules, followed by color development with a Griess reagent in acidic medium that is measured spectrophotometrically at 540 nm; the results are expressed as nmol/g tissue [29]. The GSH determination method is based on the reduction of Ellman’s reagent by thiol groups of GSH to produce 5-thio-2-nitrobenzoic acid that has a yellow color, which was measured spectrophotometrically at 412 nm and expressed as nmol/g tissue [30]. Cardiac SOD activity was measured colorimetrically at 420 nm by the method that is based on the inhibition of pyrogallol autooxidation by SOD, and the results were expressed as U/g tissue [31].
2.6. Determination of Cardiac TLR4. Total RNA was extracted from a cardiac tissue homogenate using the Ribo-Zol Reagent (AMRESCO, Solon, OH, USA) according to the manufacturer’s instructions. Real-time PCR was performed with 50 ng of RNA template per reaction using the SensiFAST™ SYBR® Hi-ROX One-Step Kit (Meridian Bioscience Inc./Bioline; Memphis, TN, USA) in 25 μl reaction volume containing 70 nM of specific primers in the Applied Biosystems 7500 Fast Real-Time PCR System (Foster City, CA, USA). Sequences of the primers were as follows: TLR4 forward primer, 5′-AATCCCTGCATAGAGGTACTTCCTAAT-3′ and reverse primer, 5′-CTCAGATCTAGGTTCTTGGTTGAATAAG-3′ [32] and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) forward primer, 5′-GTCGGTGTGAACGGATTTG-3′ and reverse primer, 5′-CTTGCCGTGGGTAGAGTCAT-3′ [33]. The SYBR green data were analyzed with a relative quantification to GAPDH as a reference gene. The relative expression levels of the TLR4 gene were calculated according to VanGuilder et al. [34]. They were scaled relative to controls where control samples were set at a value of 1. For quantitative determination of cardiac TLR4 protein levels, a rat TLR4 ELISA kit was used according to the manufacturer’s instructions.

2.7. Immunohistochemical Expression of NF-κB/p65 and Caspase 3 in Cardiac Tissue. Sections were deparaffinized, hydrated, and washed with phosphate-buffered saline (PBS). Endogenous peroxidase activity was blocked using H2O2. Antigen retrieval was done by boiling sections in citrate buffer. Sections were incubated with NF-κB/p65 and caspase 3 primary antibodies and preserved overnight at 4°C. Then, sections were washed with PBS and treated with goat anti-rabbit IgG secondary antibody. Sections were incubated with the streptavidin-biotin complex, and the color was developed using diaminobenzidine and counterstained with hematoxylin. For semiquantitative analysis, the mean number of immunopositive cells was detected in ten high-power fields of the sections in all groups.

2.8. Determination of Cardiac Inflammatory Cytokines. The inflammatory cytokines TNF-α and IL-6 were determined in a cardiac homogenate using rat TNF-α and IL-6 ELISA kits according to the manufacturer’s instructions.

2.9. Statistical Analysis. GraphPad Prism software was used for statistical analysis (version 6.01 for Windows, San Diego, CA, USA). Results were expressed as means ± SEM. One-way analysis of variance (ANOVA) followed by Tukey’s postanalysis test was used to analyze the results for statistically significant difference. Differences with p value < 0.05 were considered significant.

3. Results

3.1. Effect of Paeonol Treatment on Cardiac Histopathology. Light microscopic examination of the control group showed branched cardiac muscle fibers with cross-striations, acidophilic cytoplasm, and central vesicular oval nuclei. Blood capillaries were noticed within the connective tissue stroma between the muscle fibers (Figure 1(a), Table 1). Sections of the MTX-treated group showed fragmented necrotic muscle fibers that appeared widely separated. Some fibers assumed apoptotic morphology with hyperacidophilic cytoplasm.
nuclear pyknosis, and nuclear fragmentation. Many areas of hemorrhage and congestion were noticed (Figures 1(b1) and 1(b2), Table 1). In the paeonol+MTX group, most of the cardiac muscle fibers retained their normal appearance. Few scattered areas showed degenerated fibers. Many blood capillaries appeared dilated and congested (Figure 1(c), Table 1). Our preliminary experiments showed that paeonol alone had no effect on cardiac histopathology and oxidative stress markers (data are not shown).

3.2. Effect of Paeonol on Cardiac Oxidative and Nitrosative Stress Markers. In the MTX group, there was an increase in cardiac NOX-2, MDA, and NO levels, while there was a decrease in the level of GSH and in the activity of SOD in comparison to the normal control rats. Oral treatment with paeonol before MTX challenge significantly decreased the NOX-2, MDA, and NO levels and increased the level of GSH and the activity of SOD in comparison with the MTX group (Table 2).

3.3. Effect of Paeonol Treatment on Cardiac TLR4 mRNA Expression and Protein Level. MTX-treated rats showed a significant increase in TLR4 mRNA expression in comparison to normal control rats. Paeonol pretreatment significantly decreased the TLR4 mRNA expression; however, it was still significantly higher than the normal control rats (Figure 2(a)). The same pattern was seen with the TLR4 protein level (Figure 2(b)).

3.4. Effect of Paeonol Treatment on Cardiac NF-κB/p65 Immunostaining. Immunohistochemical staining of NF-κB/p65 in the control group showed positive expression in the cytoplasm of scattered cells of the endomyxium. The endothelium of the blood vessels showed either negative or low cytoplasmic expression (Figure 3(a)). However, the MTX-treated group showed positive cytoplasmic and nuclear expression in many cells. The endothelium of the blood vessels also showed high expression (Figure 3(b)). On the other hand, the paeonol+MTX group showed positive expression in a few scattered cells and low expression in the endothelium (Figure 3(c)). Semiquantitative analysis showed a significant increase \( (p < 0.05) \) in the mean number of the NF-κB immunopositive cells in the MTX group compared to the control group. On the other hand, there was a significant decrease \( (p < 0.05) \) in the mean number of the immunopositive cells in the paeonol+MTX group compared to the MTX group (Figure 3(d)).

3.5. Effect of Paeonol Treatment on Cardiac Inflammatory Cytokines. MTX-intoxicated rats showed a significant increase in TNF-α and IL-6 levels in comparison with the control group. Paeonol-treated rats showed a significant decrease in these inflammatory cytokines compared to MTX-challenged rats (Figures 4(a) and 4(b)).

3.6. Effect of Paeonol Treatment on Cardiac Caspase 3 Immunostaining. Immunohistochemical staining of caspase 3 revealed minimal expression in control animals (Figure 5(a)). The MTX-treated group showed high cytoplasmic and nuclear expression in many cells (Figure 5(b)). Paeonol+MTX animals had a positive expression only in scattered cells (Figure 5(c)). Semiquantitative analysis showed a significant increase \( (p < 0.05) \) in the mean number of the caspase 3 immunopositive cells in the MTX group compared to the control group. On the other hand, there was a significant decrease \( (p < 0.05) \) in the mean number of the immunopositive cells in the paeonol+MTX group compared to the MTX group (Figure 5(d)).

4. Discussion

Cardiac toxicity after large doses of MTX was previously reported in the form of arrhythmias, hypotension, and cardiac arrest [5, 35], which necessitates multiple studies to evaluate agents with cardiac protective activities against the MTX-induced damage [7, 8]. The current results indicated that MTX treatment resulted in cardiac tissue damage manifested by histopathological changes of cardiac tissues. These results are in accordance with the findings of Tousson et al. [7] who reported that MTX treatment was associated with many histopathological abnormalities in rat cardiac tissues. On the other hand, in the present study, the alleviation of histopathologically examined MTX-induced cardiac tissue damage by paeonol is in line with the results of Wu et al. [16], who found that epirubicin-induced cardiac injuries were characterized by cytoplasmic vacuolization and interstitial hemorrhage; however, paeonol noticeably decreased this severe damage. Moreover, paeonol improved isoproterenol-induced myocardial histological changes as necrotic changes in myofibrils with intense infiltration of neutrophil granulocytes and interstitial edema in rats [14].

MTX-induced oxidative and nitrosative stress plays an important role in the development and progression of MTX multiorgan toxicity including the heart [4, 7, 8]. MTX is known to elevate reactive oxygen species (ROS) by the elevation of homocysteine that is rapidly autooxidized forming ROS [36], reduction of NADPH that is utilized by glutathione reductase to retain the reduced state of glutathione that protects against ROS [37], and activation of NOX that generates ROS [38]. In the present study, MTX-induced oxidative cardiac tissue damage with disturbed oxidant/antioxidant balance is expressed as a significant increase in cardiac NOX-2 and MDA levels with a concurrent decrease in cardiac GSH level and SOD activity. In addition, MTX significantly increased the nitrosative stress marker NO level. These results are in accordance with the findings of Abdel-Daim et al. [8] who reported that MTX treatment was
Table 2: Effect of paeonol on NADPH oxidase- (NOX-) 2, malondialdehyde (MDA), nitric oxide (NO), and reduced glutathione (GSH) levels along with superoxide dismutase (SOD) activity in methotrexate- (MTX-) induced cardiac toxicity in rats.

| Groups      | NOX-2 (ng/ml) | MDA (nmol/g tissue) | NO (nmol/g tissue) | GSH (nmol/g tissue) | SOD (U/g tissue) |
|-------------|---------------|---------------------|--------------------|---------------------|------------------|
| Control     | 1.68 ± 0.10   | 27.20 ± 2.62        | 788.8 ± 73.8       | 1261 ± 13.4         | 5362 ± 350       |
| MTX         | 6.01 ± 0.27a  | 56.77 ± 5.54a       | 3594 ± 244a        | 489.4 ± 41.7a       | 522.3 ± 47.4a    |
| Paeonol+MTX | 3.18 ± 0.13ab | 29.84 ± 0.43b       | 1780 ± 32.4ab      | 751.6 ± 59.1ab      | 4678 ± 445b      |

All parameters are expressed as means ± SEM of 6 observations. Significant difference is reported when \( p < 0.05 \). "a" means significant difference compared to the control group and "b" means significant difference compared to the MTX-treated group.

Figure 2: Effect of paeonol (PAE) on cardiac Toll-like receptor 4 (TLR4) mRNA expression (a) and protein level (b) in methotrexate- (MTX-) induced cardiac toxicity in rats. All parameters are expressed as means ± SEM. "A" means significantly different from the control group and "B" means significantly different from the MTX-treated group.

Mediators of Inflammation

associated with a significant increase in MDA and NO levels together with a significant decrease in the GSH level and SOD activity.

The results of the present study have shown that paeonol prevents MTX-induced NOX-2 increase. In agreement with these results, paeonol decreased NOX-2 in rat primary microglia [39] and human primary chondrocytes [40]. In the current study, the ability of paeonol to significantly improve cardiac GSH level and SOD activity along with a decrease in MDA level is consistent with the finding of Li et al. [41] who reported that paeonol significantly increased cardiac GSH level and SOD activity besides decreasing MDA level in isoproterenol-induced myocardial injury in rats. NOX isoforms are a principal source of cardiac ROS and are associated with a wide range of cardiovascular diseases such as hypertension, atherosclerosis, heart failure, and cardiac arrhythmias [42]. GSH, a tripeptide nonenzymatic antioxidant, performs an essential role in antioxidant protection directly via scavenging ROS and indirectly via working as a cofactor of antioxidant enzymes [43]. SOD, an important first line antioxidant enzyme, catalyzes the dismutation of the superoxide radical into either molecular oxygen or hydrogen peroxide [44]. The inhibitory effect of paeonol on lipid peroxidation, assessed as MDA, could be secondary to its antioxidant activity and/or its repressing effect on inducible NO synthase- (iNOS-) mediated NO bioavailability [45, 46].

In harmony with the present study, several previous studies [47, 48] noted similar findings regarding the ability of paeonol to decrease the NO level. NO, a short-lived gasotransmitter, is known as a mediator and regulator of inflammatory responses. High levels of iNOS-derived NO are produced in response to inflammatory stimuli and mediate proinflammatory and destructive effects. These effects are mediated indirectly by a very quick interaction of NO with reactive oxygen species, which are synthesized by activated inflammatory cells resulting in the formation of the cytotoxic reactive nitrogen species peroxynitrite [49]. In addition, NO can activate NF-κB, a transcription factor that controls many genes involved in inflammation [50]. NF-κB is constitutively bound to inhibitor of κB (IκB) molecules, which confine its localization to the cytosol. After engagement of TLRs, signaling through MyD88 results in the phosphorylation of IκB kinase. Phosphorylation of serine residues on IκB promotes its degradation, thereby freeing NF-κB to enter the nucleus and activate the transcription of target inflammatory genes. NF-κB-regulated genes direct the differentiation of distinct immune cell types as macrophages. Differentiated macrophages produce different cytokines as TNF-α and IL-6 [51].

The present study showed that the MTX-induced cardiac inflammatory response (NF-κB/TNF-α/IL-6) can be evidence of the increased cardiac TLR4 mRNA expression and protein level. These results are in accord with previous studies that demonstrated the MTX-induced increase in TLR4 and TNF-α mRNA [52] and NF-κB/p65 immunostaining and TNF-α protein level [53] in the rat intestine. Moreover, Famurewa et al. [54] reported that MTX increased the IL-6 level in MTX-induced oxidative stress and inflammation in rats. On the other hand, in agreement with the current study, paeonol decreased the TLR4/NF-κB/TNF-α/IL-6 inflammatory signaling pathway in lipopolysaccharide-induced acute
lung injury [55] and IL-1β-induced human fibroblast-like synoviocyte rheumatoid arthritis [56]. Stimulation of TLR4 produces the activation of NF-κB, which induces the generation of proinflammatory cytokines including TNF-α and IL-6 [17]. TLR4 also activates NOX to produce ROS [57]. In addition, inflammation and oxidative stress are interrelated as oxidative stress is involved in the activation of NF-κB and the latter can induce oxidative stress [58], so it is difficult to predict a specific cause/effect relationship between them.

Caspase 3, a key enzyme in apoptosis, is activated in apoptotic cells through both extrinsic and intrinsic pathways.
The MTX-induced increase of caspase 3 has been reported in multiorgan toxicity [4, 25, 53, 60, 61]. Our results showed a significant increase in caspase 3 expression in response to MTX treatment. NF-κB/p65 activation is required for endoplasmic reticulum stress-mediated apoptosis in cardiomyocytes [62]. Alternatively, stimulation of cardiomyocytes with ROS causes apoptosis [63]. Accordingly, in the current study, the effect of paeonol on caspase 3 expression, which concurs with various previous studies [12, 16], appears to be secondary to its antioxidant and anti-inflammatory activities. Remarkably, paeonol increased apoptosis and enhanced the cytotoxic effects of various anticancer drugs, such as doxorubicin [64], paclitaxel [65], and epirubicin [66]. Moreover, paeonol alone had its own cytotoxic effect [67, 68].

5. Conclusion

In summary, paeonol attenuates MTX-induced cardiac toxicity in rats partly through ameliorating oxidative stress by decreasing the NOX-2 level and preserving the level of GSH and activity of SOD as well as inhibiting the expression of the TLR4/NF-κB/TNF-α/IL-6 inflammatory pathway. This was associated with a decrease in the level of the proapoptotic marker, caspase 3.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors report no conflicts of interest.

Acknowledgments

This work was supported by the Deanship of Scientific Research, King Faisal University, Al-Ahsa, Saudi Arabia (project number 150106).

References

[1] M. Joerger, A. D. Huitema, G. Illerhaus, and A. J. Ferreri, "Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma," Leukemia & Lymphoma, vol. 53, no. 10, pp. 1867–1875, 2012.

[2] P. Cipriani, P. Ruscitti, F. Carubbi, V. Liakouli, and R. Giacomelli, "Methotrexate: an old new drug in autoimmune disease," Expert Review of Clinical Immunology, vol. 10, no. 11, pp. 1519–1530, 2014.

[3] M. Sramek, J. Neradil, and R. Veselska, "Much more than you expected: the non-DHFR-mediated effects of methotrexate,”
Biochimica et Biophysica Acta - General Subjects, vol. 1861, no. 3, pp. 499–503, 2017.

[4] A. A. El-Sheikh, M. A. Morsy, A. M. Abdalla, A. H. Hamouda, and I. A. Alhaider, "Mechanisms of thymoquinone hepatoprotective effect in methotrexate-induced toxicity in rats," Mediators of Inflammation, vol. 2015, Article ID 859383, 12 pages, 2015.

[5] A. Perez-Verdia, F. Angulo, F. L. Hardwicke, and K. M. Nugent, "Acute cardiac toxicity associated with high-dose intravenous methotrexate therapy: case report and review of the literature," Pharmacotherapy, vol. 25, no. 9, pp. 1271–1276, 2005.

[6] K. Bartyik, S. Turi, F. Orosz, and E. Karg, "Methotrexate inhibits the glyoxalase system in vivo in children with acute lymphoid leukemia," European Journal of Cancer, vol. 40, no. 15, pp. 2287–2292, 2004.

[7] E. Tousson, E. Hafez, S. Zaki, and A. Gad, "The cardioprotective effects of L-carnitine on rat cardiac injury, apoptosis, and oxidative stress caused by amphoterin," Environmental Science and Pollution Research International, vol. 23, no. 20, pp. 20600–20608, 2016.

[8] M. M. Abdel-Daim, H. A. Khalifa, A. I. Abushouk, M. A. Dkhil, and S. A. Al-Quraishy, "Diosmin attenuates methotrexate-induced hepatic, renal, and cardiac injury: a biochemical and histopathological study in mice," Oxidative Medicine and Cellular Longevity, vol. 2017, Article ID 3281670, 10 pages, 2017.

[9] X. Jin, J. Wang, Z. M. Xia et al., "Anti-inflammatory and anti-oxidative activities of paenol and its metabolites through blocking MAPK/ERK/p38 signaling pathway," Inflammation, vol. 39, no. 1, pp. 434–446, 2016.

[10] F. Xu, H. Xiao, R. Lju et al., "Paeonol ameliorates glucose and lipid metabolism in experimental diabetes by activating Akt," Frontiers in Pharmacology, vol. 10, p. 261, 2019.

[11] Q. Li, Y. Zhang, J. Sun, and Q. Bo, "Paeonol-mediated apoptosis of hepatocellular carcinoma cells by NF-κB pathway," Oncology Letters, vol. 17, no. 2, pp. 1761–1767, 2019.

[12] H. M. Hafez, M. A. Morsy, M. Z. Mohamed, and N. M. Zendom, "Mechanisms underlying cardioprotective effect of paenol against indomethacin-induced ulcer in rats," Human & Experimental Toxicology, vol. 38, no. 5, pp. 510–518, 2019.

[13] S. Wu, L. Liu, S. Yang et al., "Paeonol alleviates CCl4-induced liver fibrosis through suppression of hepatic stellate cells activation via inhibiting the TGF-β/Smad3 signaling," Immuno-pharmacology and Immunotoxicology, vol. 41, no. 3, pp. 438–445, 2019.

[14] H. Li, F. Song, L. R. Duan et al., "Paeonol and danshensu combination attenuates apoptosis in myocardial infarcted rats by inhibiting oxidative stress: roles of Nr2f2/HO-1 and PI3K/Akt pathway," Scientific Reports, vol. 6, p. 23569, 2016.

[15] H. Lee, G. Lee, H. Kim, and H. Bae, "Paeonol, a major compound of moutan cortex, attenuates cisplatin-induced nephrotoxicity in mice," Evidence-based Complementary and Alternative Medicine, vol. 2013, Article ID 310989, 7 pages, 2013.

[16] J. Wu, C. Sun, R. Wang et al., "Cardioprotective effect of paenol against euripin-induced heart injury via regulating miR-1 and PI3K/Akt pathway," Chemico-Biological Interactions, vol. 286, pp. 17–25, 2018.

[17] A. Roy, M. Srivastava, U. Saqib et al., "Potential therapeutic targets for inflammation in toll-like receptor 4 (TLR4)-mediated signaling pathways," International Immunopharmacology, vol. 40, pp. 79–89, 2016.

[18] J. H. Boyd, S. Mathur, Y. Wang, R. M. Bateman, and K. R. Walley, "Toll-like receptor stimulation in cardiomyocytes decreases contractility and initiates an NF-kappaB dependent inflammatory response," Cardiovascular Research, vol. 72, no. 3, pp. 384–393, 2006.

[19] D. Fairweather, S. Yusung, S. Frisianco et al., "IL-12 receptor β1 and Toll-like receptor 4 increase IL-1β- and IL-18-associated myocarditis and coxsackievirus replication," Journal of Immunology, vol. 170, no. 9, pp. 4731–4737, 2003.

[20] H. Soraya, A. S. Clanchan, M. Rameshred, N. Maleki-Dizaji, M. Ghazi-Khansari, and A. Garjani, "Chronic treatment with metformin suppresses toll-like receptor 4 signaling and attenuates left ventricular dysfunction following myocardial infarcion," European Journal of Pharmacology, vol. 737, pp. 77–84, 2014.

[21] H. S. Ding, J. Yang, P. Chen et al., "The HMGB1–TLR4 axis contributes to myocardial ischemia/reperfusion injury via regulation of cardiomyocyte apoptosis," Gene, vol. 527, no. 1, pp. 389–393, 2013.

[22] L. Liu, Y. Wang, Z. Y. Cao et al., "Up-regulated TLR4 in cardiomyocytes exacerbates heart failure after long-term myocardial infarction," Journal of Cellular and Molecular Medicine, vol. 19, no. 12, pp. 2728–2740, 2015.

[23] S. Ehrentraut, R. Lohner, M. Schwederski et al., "In vivo Toll-like receptor 4 antagonism restores cardiac function during endotoxemia," Shock, vol. 36, no. 6, pp. 613–620, 2011.

[24] M. C. Louwe, J. C. Karper, M. R. de Vries et al., "RP105 deficiency aggravates cardiac dysfunction after myocardial infarction in mice," International Journal of Cardiology, vol. 176, no. 3, pp. 788–793, 2014.

[25] A. A. El-Sheikh, M. A. Morsy, and A. Y. Al-Taher, "Protective mechanisms of resveratrol against methotrexate-induced renal damage may involve BCRP/ABCG2," Fundamental & Clinical Pharmacology, vol. 30, no. 5, pp. 406–418, 2016.

[26] J. Liu, S. Wang, L. Feng et al., "Hypoglycemic and antioxidant activities of paenol and its beneficial effect on diabetic encephalopathy in streptozotocin-induced diabetic rats," Journal of Medicinal Food, vol. 16, no. 7, pp. 577–586, 2013.

[27] H. Moreno Júnior, L. P. Nathan, K. Metze et al., "Non-specific inhibitors of nitric oxide synthase cause myocardial necrosis in the rat," Clinical and Experimental Pharmacology & Physiology, vol. 24, no. 5, pp. 349–352, 1997.

[28] J. A. Buege and S. D. Aust, "Microsomal lipid peroxidation," Methods in Enzymology, vol. 52, pp. 302–310, 1978.

[29] K. V. Sastry, R. P. Moudgal, J. Mohan, J. S. Tyagi, and G. S. Rao, "Spectrophotometric determination of serum nitrite and nitrate by copper-cadmium alloy," Analytical Biochemistry, vol. 306, no. 1, pp. 79–82, 2002.

[30] M. S. Moron, J. W. Depierre, and B. Mannervik, "Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver," Biochimica et Biophysica Acta, vol. 882, no. 1, pp. 67–78, 1979.

[31] S. Marklund and G. Marklund, "Involvement of the superoxide anion radical in the autoxidation of pyrogalol and a convenient assay for superoxide dismutase," European Journal of Biochemistry, vol. 47, no. 3, pp. 469–474, 1974.
Mediators of Inflammation

model of necrotizing enterocolitis,” PLoS One, vol. 2, no. 10, article e1102, 2007.

[33] I. Wimmer, A. R. Tröschner, F. Brunner et al., “Systematic evaluation of RNA quality, microarray data reliability and pathway analysis in fresh, fresh frozen and formalin-fixed paraffin-embedded tissue samples,” Scientific Reports, vol. 8, no. 1, p. 6351, 2018.

[34] H. D. VanGuilder, K. E. Vrana, and W. M. Freeman, “Twenty-five years of quantitative PCR for gene expression analysis,” BioTechniques, vol. 44, no. 5, pp. 619–626, 2008.

[35] O. M. Fuskevăg, C. Kristiansen, S. Lindal, and J. Aarbakke, “Leucovorin and maximum tolerated dose toxicity of methotrexate in rats,” Pediatric Hematology and Oncology, vol. 17, no. 8, pp. 651–658, 2000.

[36] G. N. Welch and J. Loscalzo, “Homocysteine and atherothrombosis,” The New England Journal of Medicine, vol. 338, no. 15, pp. 1042–1050, 1998.

[37] R. M. Babiak, A. P. Campello, E. G. Carnieri, and M. B. Oliveira, “Methotrexate: pentose cycle and oxidative stress,” Cellular Biochemistry and Function, vol. 16, no. 4, pp. 283–293, 1998.

[38] H. H. Arab, S. A. Salama, and I. A. Maghrabi, “Camel milk attenuates methotrexate-induced kidney injury via activation of PI3K/Akt/eNOS signaling and intervention with oxidative aberrations,” Food & Function, vol. 9, no. 5, pp. 2661–2672, 2018.

[39] Y. T. Tseng, Y. Y. Hsu, Y. T. Shih, and T. Horie, “Disruption of ZO-1-claudin-4 interaction in relation to inflammatory responses in methotrexate-induced intestinal mucositis,” Cancer Chemotherapy and Pharmacology, vol. 72, no. 4, pp. 757–765, 2013.

[40] A. A. El-Sheikh, M. A. Morsy, and A. H. Hamouda, “Protective mechanisms of thymoquinone on methotrexate-induced intestinal toxicity in rats,” Pharmacogn Mag, vol. 12, no. 1, pp. 76–81, 2016.

[41] A. C. Famurewa, A. M. Folawiyo, E. B. Enohnyaket et al., “Beneficial role of virgin coconut oil supplementation against acute methotrexate chemotherapy-induced oxidative toxicity and inflammation in rats,” Integrative Medicine Research, vol. 7, no. 3, pp. 257–263, 2018.

[42] F. Wang, M. Zhu, N. Jiang, M. Zhang, L. Feng, and X. Jia, “Paeonol ameliorates lipopolysaccharides-induced acute lung injury by regulating TLR4/MyD88/NF-κB signaling pathway,” Die Pharmazie, vol. 74, no. 2, pp. 101–106, 2019.

[43] K. F. Zhai, H. Duan, L. Luo et al., “Cardioprotective effect of paeonol and danshen combination on isoproterenol-induced myocardial injury in rats,” PLoS One, vol. 7, no. 11, article e48872, 2012.

[44] Y. Zhang, P. Murugesan, K. Huang, and H. Cai, “NADPH oxidases and oxidase crosstalk in cardiovascular diseases: novel therapeutic targets,” Nature Reviews Cardiology, pp. 1–25, 2019.

[45] R. Franco, O. J. Schoneveld, A. Pappa, and M. I. Panayiotidis, “The central role of glutathione in the pathophysiology of human diseases,” Archives of Physiology and Biochemistry, vol. 113, no. 4–5, pp. 234–258, 2007.

[46] L. Lewandowski, M. Kępinska, and H. Milnerowicz, “The copper-zinc superoxide dismutase activity in selected diseases,” European Journal of Clinical Investigation, vol. 49, no. 1, article e13036, 2019.

[47] H. S. Chae, O. H. Kang, Y. S. Lee et al., “Inhibition of LPS-induced iNOS, COX-2 and inflammatory mediator expression by paeonol through the MAPKs inactivation in RAW 264.7 cells,” The American Journal of Chinese Medicine, vol. 37, no. 1, pp. 181–194, 2009.

[48] M. S. Goligorsky, S. V. Brodsky, and E. Noiri, “Nitric oxide in acute renal failure: NOS versus NOS,” Kidney International, vol. 61, no. 3, pp. 855–861, 2002.

[49] Y. Lou, C. Wang, Q. Tang et al., “Paeonol inhibits IL-1β-induced inflammation via PI3K/Akt/NF-κB pathways: in vivo and vitro studies,” Inflammation, vol. 40, no. 5, pp. 1698–1706, 2017.

[50] X. Sun, P. Wang, L. P. Yao et al., “Paeonol alleviated acute alcohol-induced liver injury via SIRT1/Nrf2/NF-κB signaling pathway,” Environmental Toxicology and Pharmacology, vol. 60, pp. 110–117, 2018.

[51] R. Korhonen, A. Lahti, H. Kankaanranta, and E. Moilanen, “Nitric oxide production and signaling in inflammation,” Current Drug Targets. Inflammation and Allergy, vol. 4, no. 4, pp. 471–479, 2005.

[52] C. Hierholzer, B. Harbrecht, J. M. Menezes et al., “Essential role of induced nitric oxide in the initiation of the inflammatory response after hemorrhagic shock,” The Journal of Experimental Medicine, vol. 187, no. 6, pp. 917–928, 1998.

[53] R. G. Baker, M. S. Hayden, and S. Ghosh, “NF-κB inflammation, and metabolic disease,” Cell Metabolism, vol. 13, no. 1, pp. 11–22, 2011.

[54] K. Hamada, N. Kakigawa, S. Sekine, Y. Shitara, and T. Horie, “Disruption of ZO-1-claudin-4 interaction in relation to inflammatory responses in methotrexate-induced intestinal mucositis,” Cancer Chemotherapy and Pharmacology, vol. 72, no. 4, pp. 757–765, 2013.

[55] A. A. El-Sheikh, M. A. Morsy, and A. H. Hamouda, “Protective mechanisms of thymoquinone on methotrexate-induced intestinal toxicity in rats,” Pharmacogn Mag, vol. 12, no. 1, pp. 76–81, 2016.

[56] A. C. Famurewa, A. M. Folawiyo, E. B. Enohnyaket et al., “Beneficial role of virgin coconut oil supplementation against acute methotrexate chemotherapy-induced oxidative toxicity and inflammation in rats,” Integrative Medicine Research, vol. 7, no. 3, pp. 257–263, 2018.

[57] F. Wang, M. Zhu, N. Jiang, M. Zhang, L. Feng, and X. Jia, “Paeonol ameliorates lipopolysaccharides-induced acute lung injury by regulating TLR4/MyD88/NF-κB signaling pathway,” Die Pharmazie, vol. 74, no. 2, pp. 101–106, 2019.

[58] K. F. Zhai, H. Duan, L. Luo et al., “Protective effects of paeonol on inflammatory response in IL-1β-induced human fibroblast-like synoviocytes and rheumatoid arthritis progression via modulating NF-κB pathway,” Inflammopharmacology, vol. 25, no. 5, pp. 523–532, 2017.

[59] L. T. Hsieh, H. Frey, M. V. Nastase et al., “Bimodal role of NADPH oxidases in the regulation of biglycan-triggered IL-1β synthesis,” Matrix Biology, vol. 49, pp. 61–81, 2016.

[60] S. K. Biswas, “Does the interdependence between oxidative stress and inflammation explain the antioxidant paradox?”, Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 5698931, 9 pages, 2016.

[61] S. Elmore, “Apoposis: a review of programmed cell death,” Toxicologic Pathology, vol. 35, no. 4, pp. 495–516, 2007.

[62] H. T. Papaconstantinou, C. Xie, W. Zhang et al., “The role of caspases in methotrexate-induced gastrointestinal toxicity,” Surgery, vol. 130, no. 5, pp. 859–865, 2001.

[63] E. M. Fikry, W. A. Hassan, and A. M. Gad, “Bone marrow and adipose mesenchymal stem cells attenuate cardiac fibrosis induced by methotrexate in rats,” Journal of Biochemical and Molecular Toxicology, vol. 31, no. 11, article e21970, 2017.

[64] T. Hamid, S. Z. Guo, J. R. Kingery, X. Xiang, B. Dawn, and S. D. Prabhu, “Cardiomyocyte NF-κB p65 promotes adverse remodelling, apoptosis, and endoplasmic reticulum stress in heart failure,” Cardiovascular Research, vol. 89, no. 1, pp. 129–138, 2011.
[63] R. von Harsdorf, P.-F. Li, and R. Dietz, “Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis,” *Circulation*, vol. 99, no. 22, pp. 2934–2941, 1999.

[64] L. Fan, B. Song, G. Sun, T. Ma, F. Zhong, and W. Wei, “Endoplasmic reticulum stress-induced resistance to doxorubicin is reversed by paenol treatment in human hepatocellular carcinoma cells,” *PLoS One*, vol. 8, no. 5, article e62627, 2013.

[65] W. Zhang, J. Cai, S. Chen et al., “Paclitaxel resistance in MCF-7/PTX cells is reversed by paenol through suppression of the SET/phosphatidylinositol 3-kinase/Akt pathway,” *Molecular Medicine Reports*, vol. 12, no. 1, pp. 1506–1514, 2015.

[66] J. Wu, X. Xue, B. Zhang et al., “Enhanced antitumor activity and attenuated cardiotoxicity of epirubicin combined with paenol against breast cancer,” *Tumour Biology*, vol. 37, no. 9, pp. 12301–12313, 2016.

[67] R. O. Saahene, J. Wang, M. L. Wang, E. Agbo, and D. Pang, “The antitumor mechanism of paenol on CXCL4/CXCR3-B signals in breast cancer through induction of tumor cell apoptosis,” *Cancer Biotherapy & Radiopharmaceuticals*, vol. 33, no. 6, pp. 233–240, 2018.

[68] D. Ramachandhiran, V. Vinothkumar, and S. Babukumar, “Paenol exhibits anti-tumor effects by apoptotic and anti-inflammatory activities in 7,12-dimethylbenz(a)anthracene induced oral carcinogenesis,” *Biotechnic & Histochemistry*, vol. 94, no. 1, pp. 10–25, 2019.